Myocardial fibrosis critically contributes to cardiac dysfunction in inflammatory dilated cardiomyopathy (iDCM). Activation of transforming growth factor-b (TGF-b) signalling is a key-step in promoting tissue remodelling and fibrosis in iDCM. Downstream mechanisms controlling these processes, remain elusive.
Methods and results
Experimental autoimmune myocarditis (EAM) was induced in BALB/c mice with heart-specific antigen and adjuvant. Using heart-inflammatory precursors, as well as mouse and human cardiac fibroblasts, we demonstrated rapid secretion of Wnt proteins and activation of Wnt/b-catenin pathway in response to TGF-b signalling. Inactivation of extracellular Wnt with secreted Frizzled-related protein 2 (sFRP2) or inhibition of Wnt secretion with Wnt-C59 prevented TGF-b-mediated transformation of inflammatory precursors and cardiac fibroblasts into pathogenic myofibroblasts. Inhibition of T-cell factor (TCF)/b-catenin-mediated transcription with ICG-001 or genetic loss of b-catenin also prevented TGF-b-induced myofibroblasts formation. Furthermore, blocking of Smad-independent TGF-b-activated kinase 1 (TAK1) pathway completely abrogated TGF-b-induced Wnt secretion. Activation of Wnt pathway in the absence of TGF-b, however, failed to transform precursors into myofibroblasts. The critical role of Wnt axis for cardiac fibrosis in iDCM is also supported by elevated Wnt-1/Wnt-5a levels in human samples from hearts with myocarditis. Accordingly, and as an in vivo proof of principle, inhibition of Wnt secretion or TCF/b-catenin-mediated transcription abrogated the development of post-inflammatory fibrosis in EAM.
Conclusion
We identified TAK1-mediated rapid Wnt protein secretion as a novel downstream key mechanism of TGF-b-mediated myofibroblast differentiation and myocardial fibrosis progression in human and mouse myocarditis. Thus, pharmacological targeting of Wnts might represent a promising therapeutic approach against iDCM in the future.
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Introduction
Inflammatory dilated cardiomyopathy (iDCM) is a distinct entity among the specific heart muscle diseases and is defined as cardiac dysfunction due to myocardial inflammation. Following acute myocarditis, patients may develop progressive heart failure in up to 30% of cases with survival rate ,40% after 10 years.
1,2 Dilation of heart chambers, impaired systolic function, and myocardial fibrosis are hallmarks of the typical end-stage heart failure phenotype in iDCM. 1, 2 Progressive pathological remodelling and excessive accumulation of myofibroblasts following cardiac inflammation is a major cause of heart dysfunction in iDCM. 3 -5 Myofibroblasts produce fibrillar collagen, mainly type I, which decreases cardiac compliance and impairs both systolic and diastolic heart function, as evidenced by echocardiography or magnetic resonance. 5 -8 So far, little is known about cellular and molecular mechanisms regulating transition of acute myocarditis into iDCM and end-stage heart failure phenotype. Experimental autoimmune myocarditis (EAM) represents a rodent model of iDCM. Immunization of susceptible animals with myosin heavy chain-a (aMyHC) peptide together with a strong adjuvant results in CD4 + T-cell-mediated myocarditis. Inflammation peaks 14-21 Days after the first immunization. Later on, inflammation largely resolves, but some animals develop the typical end-stage heart failure phenotype, including ventricular dilation and myocardial fibrosis. 4, 5, 9 In the EAM, transforming growth factor-b (TGF-b) signalling controls the transition from myocarditis to post-inflammatory fibrosis phenotype. 3 We recently demonstrated that multipotent CD133 + progenitors infiltrating the heart during myocarditis convert into collagen-producing myofibroblasts when exposed to TGF-b1. In fact, inflammatory CD133 + cells represent the major cellular source of post-inflammatory myofibroblasts in EAM. 3, 4 Transforming growth factor-b signalling plays a crucial role in embryonic development, tissue homeostasis, and pathogenesis of a variety of diseases. Active TGF-b binds to the transmembrane TGF-b type II receptor, which in turn recruits and activates the TGF-b type I receptor initiating canonical Smad signalling by phosphorylation of Smad2 and Smad3 proteins. 7, 10 Stimulated TGF-b type I receptor also activates a number of Smad-independent signalling cascades distinctly from transcription. Polyubiquitination and autophosphorylation of TGF-b-activated kinase 1 (TAK1) represents an example of non-canonical pathway activated by TGF-b1.
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Wnt signalling represents another important molecular pathway regulating developmental processes and tissue pathogenesis. The family of Wnt ligands consists of highly evolutionarily conserved glycoproteins, which after binding to receptor complexes can trigger various outputs including b-catenin-dependent (canonical) or independent (non-canonical) responses. 12 In canonical response, binding of Wnt ligands to Frizzled/Low Density Lipoprotein Receptorrelated Proteins receptor complexes initiates a series of molecular events resulting in cytoplasmic stabilization of b-catenin, which is subsequently translocated to the nucleus. In the nucleus, b-catenin complexes with the TCF (T-cell factor)/LEF (lymphoid enhancer factor) transcription factors to initiate the transcription of Wnt target genes. 13 Figure S1 ). To address whether Wnt signalling was essential for transformation of precursor cells into myofibroblasts, we differentiated inflammatory CD133
+ cells and cardiac fibroblasts (alternative source of pathogenic cardiac myofibroblasts) with TGF-b1 in the presence or absence of physiological Wnt inhibitor sFRP2, which sequesters Wnt ligands and thus prevents their association to receptor complexes. Addition of sFRP2 to TGF-b1-treated cells inhibited Wnt target gene expression ( Figure 1A and B), nearly completely prevented formation of fibronectin + /aSMA + myofibroblasts, and inhibited TGF-b-induced contraction ( Figure 1C and D) . Accordingly, we found that the expression of genes characteristic for myofibroblasts including Acta, Fn1, Col1a1, and Tnc and involved in tissue remodelling such as Mmp8, Mmp9, Timp2, and Timp3 were impaired in TGF-b1-treated cells cultured in the presence of sFRP2 ( Figure 1E ).
Transforming growth factor-b triggers Wnt secretion and activation of the canonical Wnt pathway
Gene expression analysis showed that addition of sFRP2 prevented expression of the common Wnt target genes in response to TGF-b1 treatment. These findings prompted us to measure secreted Wnt proteins. In the canonical response, Wnts activate TCF/LEF transcription factor complex through b-catenin. Figure S2 ). Wnt protein secretion can be blocked with Porcupine inhibitor Wnt-C59. Addition of Wnt-C59 to TGF-b1-treated cells abrogated TGF-b1-induced expression of Wnt target genes and myofibroblast-specific genes ( Figure 3A and B) and prevented formation of aSMA + myofibroblasts ( Figure 3C ).
T-cell factor/b-catenin-mediated transcriptional activation is crucial for transforming growth factor-b1-mediated myocardial fibrosis
To address whether TGF-b1-induced fibrosis required activation of the canonical Wnt signalling pathway, we used tankyrase inhibitor JW55 (triggering b-catenin cytoplasmic degradation and thus preventing its nuclear translocation and transcriptional activity) 19 Transforming growth factor-b-activated kinase 1 mediates transforming growth factor-b1-induced Wnt secretion
Transforming growth factor-b1 activates the canonical Smad pathway and a number of Smad-independent signalling cascades. In CD133 + cells, we observed phosphorylation of Smad2 in response to TGF-b1 (Supplementary material online, Figure S7A ). On the other hand, TGF-b triggers TAK1 phosphorylation in our model (Supplementary material online, Figure S7B ). To address which pathway triggers Wnt secretion, we used two selective inhibitors specifically blocking the canonical Smad (SB-431542) or Smad-independent TAK1 (5Z-7-oxo-zeaenol) pathway. Addition of 5Z-7-oxo-zeaenol, but not SB-431542, to TGF-b1-treated cells prevented the nuclear translocation of b-catenin and abrogated expression of Wnt target genes ( Figure 4A and B) . Next, we used supernatant of cells stimulated with TGF-b1 in the presence or absence of these two inhibitors to measure TCF/LEF activity in the reporter cells. Our results clearly showed that blockade of TAK1, but not of the Smad pathway, prevented accumulation of Wnts in supernatant in response to TGF-b1 ( Figure 4C ). Importantly, none of these inhibitors affected externally induced Wnt-3a-mediated TCF/LEF response of the reporter cells ( Figure 4D ). Our results showed that 5Z-7-oxo-zeaenol also effectively prevented TGF-b1-induced transcription of Wnts (Supplementary material online, Figure S7C ).
Co-activation of transforming growth factor-b1 and canonical Wnt signalling pathways is required for myofibroblast differentiation
Next, we asked whether Wnts in the absence of TGF-b1 could trigger myofibroblast differentiation. Wnt-1/Wnt-5a cocktail, Wnt-3a-conditioned medium, or GSK3 inhibitor-CHIR, all potently induced TCF/b-catenin-mediated transcription ( Figure 5A ). Treatment with Wnt-1/5a, Wnt-3a, or CHIR led to nuclear accumulation of b-catenin ( Figure 5B ) and induced expression of the common Wnt downstream target genes in CD133 + cells ( Figure 5C ) and cardiac fibroblasts (not shown). However, we observed only a modest up-regulation of myofibroblast-specific Wnt secretion is essential for development of post-inflammatory fibrosis and ventricular dysfunction in experimental autoimmune myocarditis
Next, we asked how the expression of Wnt ligands is regulated in the heart during EAM progression. We found that inflammatory cells infiltrating the myocardium of aMyHC/CFA-immunized mice (d21) represented potent producers of Wnt-1 and Wnt-5a. In the post-inflammatory heart (d40), elevated Wnt-1 and Wnt-5a levels were maintained in fibrotic regions including adjacent cardiomyocytes ( Figure 6A) . Importantly, we found also high levels of Wnt-1 and Wnt-5a in human heart samples with active myocarditis, which was in contrast to unaffected cardiac tissue ( Figure 7) . Injection of anti-TGF-b-blocking antibody during acute myocarditis between Days 17-22 into aMyHC/CFA-immunized mice prevents cardiac fibrosis in EAM. 3 Here, we showed that anti-TGF-b treatment suppressed expression of not only myofibroblast-specific genes, but also of Wnts and Wnt target genes in the whole myocardium, and in inflammatory CD133 + cells, respectively ( Figure 6B-D) .
To address the relevance of Wnt pathway in EAM, we treated aMyHC/CFA-immunized mice with Wnt-C59, ICG-001, or sFRP2 between Days 17 -29. In all treatments, mice were nearly completely protected from post-inflammatory fibrosis in EAM (Figure 8A-D) . Cardiac fibrosis promotes ventricular dysfunction. 4 Accordingly, in aMyHC/CFA-immunized mice treated with sFRP2, the blunted cardiac fibrosis was associated with preserved left ventricular dimensions and improved systolic function as assessed by transthoracic echocardiography at Day 60 after disease induction ( Figure 8E ).
Discussion
We previously demonstrated that TGF-b signalling controls development of myocardial fibrosis in EAM. 3, 4 Here, we further elucidated the underlying mechanisms and identified Wnt secretion followed by activation of the canonical Wnt cascade as a key downstream molecular pathway of TGF-b-mediated cardiac fibrogenesis. We observed this mechanism not only in heart inflammatory cells but also in mouse and human cardiac fibroblasts suggesting a common mechanism. We demonstrated that Wnt secretion during tissue remodelling is indeed crucial for the development of cardiac fibrosis in EAM model. Activation of b-catenin in response to TGF-b has been observed also in skin 15 and pulmonary fibroblasts. 22 Noteworthy, several lines of evidence suggest that the canonical Wnt can, in turn, positively regulate TGF-b signalling. 23 Transforming growth factor-b signalling activates canonical Smad signalling and also a number of Smad-independent signalling cascades. Using 5Z-7-oxo-zeaenol, we found that inhibition of TAK1 pathway prevented TGF-b-mediated Wnt secretion. In fibrotic processes, TAK1-dependent TGF-b signalling has been mainly implicated in the activation of MAPK-and JNK-dependent pathways.
Interestingly, MAPK and JNK kinases are activated in non-canonical pathways triggered by Wnts. Moreover, recent findings demonstrated that TAK1 activation led to Wnt-dependent transcription. 24 Our results might imply that Wnts represent extracellular mediators of TAK1-dependent activation of its downstream signalling pathways.
Although the role of Wnts in iDCM has not been addressed so far, several reports pointed to an important role of Wnt pathway in pathophysiology of ischaemic heart disease. In rodent models of myocardial infarction, sFRPs were reported to reduce fibrosis and improve cardiac function. 25, 26 Furthermore, blockade of
Frizzled receptors with the specific antagonist improved postinfarction cardiac function and reduced collagen content. 27 Recent findings showed that activation of the canonical Wnt pathway by inhibiting GSK3b in cardiac fibroblasts promoted fibrogenesis in ischaemic hearts. 28 In contrast to ischaemic heart disorders, inflammatory cells represent a major cellular compartment in myocarditis. Our results clearly demonstrated that Wnt signalling is essential for myofibroblast formation from both, cardiac fibroblasts and heart-inflammatory progenitors (CD133 + cells b-catenin-mediated transcription. Our data suggest that expression of myofibroblast-specific genes is under control of the canonical Wnt pathway. In a mouse model of pulmonary fibrosis, ICG-001
was also reported to control transcription of myofibroblast-specific genes and to revert fibrosis, 21 whereas FH-535 suppressed transformation of retinal epithelial cells into myofibroblasts. End diastolic diameter and end diastolic volume show preserved left ventricular dimension after secreted Frizzled-related protein 2 treatment. P-values were computed using the unpaired two-tailed Student's t-test; line shows mean value.
In our study, we investigated TGF-b-induced Wnt secretion in resident and inflammatory precursor cells, which represent Wnt target cells in cardiac fibrosis. Given the fact that TGF-b-dependent myofibroblast differentiation is mediated by secreted Wnts, autocrine and paracrine signalling seem to play a key role in cardiac fibrosis in vivo. All these data suggest that cardiac fibrosis depends on bioavailability of extracellular Wnts, which potentially can be produced by most of cell types in the inflamed heart.
Taken together, TAK1-dependent Wnt protein secretion represents a novel downstream key mechanism of TGF-b-mediated cardiac fibrosis and remodelling in human and mouse myocarditis (Supplementary material online, Figure S8 ). Our data also show that inhibition of Wnt signalling improved cardiac function and thus indicate that pharmacological targeting of extracellular Wnts or the canonical Wnt pathway might represent a promising therapeutic option. Such anti-fibrotic therapy in inflammatory cardiomyopathy patients potentially could prevent disease progression. Therefore, inhibition of their de novo formation could eventually lead to resolution of the established fibrotic tissue and consequently to improvement of heart function in some patients. Furthermore, targeting of Wnts or Wnt pathway might represent an attractive alternative for anti-TGF-b treatment by offering a broader range of available pharmacological compounds with well-defined function. Future studies are, however, needed to address their specific anti-fibrotic activity and potential side effects.
Supplementary material
Supplementary material is available at European Heart Journal online.
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